Region South Denmark Clinics widely implement Monsenso mHealth solution

Region South Denmark Clinics widely implement Monsenso mHealth solution

Sep 19, 2017

Region South Denmark Clinics will use the Monsenso mHealth solution to support treatment of individuals diagnosed with depression, anxiety, bipolar, schizophrenia, or borderline personality disorder.

Copenhagen, Denmark – 4, September, 2017

The Mental Health Services in the Region of Southern Denmark are currently rolling out the Monsenso mHealth solution to support the treatment of individuals with affective disorders.

Monsenso is an innovation leader in mobile health solutions for mental health. Their mHealth solution is presently used by 25 clinicians across Mental Health Services in the Region of Southern Denmark to support the treatment of individuals diagnosed with depression, anxiety, bipolar, schizophrenia or borderline personality disorder.

Thomas Lethenborg, CEO at Monsenso, said that the decision for the roll-out came as a natural progression of the collaboration between Monsenso and the Region of Southern Denmark Mental Health Services on the ENTER project and the Public-Private Innovation (PPI) Partnership.

“Monsenso and the Region South Denmark have been working on different research projects for quite some time now; it’s only natural they decide to roll out our mHealth solution widely. By implementing Monsenso Clinic, clinicians will have access to patients’ historical aggregated data which will assist them in making better decisions in regards to a person’s treatment,” Mr. Lethenborg added.

The Monsenso solution has been previously utilised during research trials at The Centre for Telepsychiatry in the Region of Southern Denmark.

Claus Faerch Head of Department at The Centre for Telepsychiatry in the Region of Southern Denmark said: “We are continuously looking to improve patient engagement, and this technology will help us to track and discover more changes in mood. Our aim is to use the technology to help support the treatment we currently provide to our patients, with views to expanding the programme to more clinicians shortly.”

The  mHealth solution is based on a double-loop treatment model. The first loop consists of a smartphone app operates as a self-management tool to provide the patient insight into how their actions may influence their disorder. Individuals can use the app to fill out routine self-assessments regarding their behaviour, such as logging the amount of hours they have slept.  Additionally, the app also collects sensor data and sends helpful notifications for when patients are reporting behaviour that may trigger symptoms of their disorder.

The second loop of the treatment model involves the clinician. Clinicians can access a web portal that is synchronised to the patient’s app. This synchronisation enables clinicians to efficiently access the data collected by the patients’ smartphones anytime and anywhere.

This comprehensive double loop feedback system aims to increase patient engagement, awareness, and informed decision making during treatment.

Click on this link to read this press release in Danish.

For additional information, please contact:
Helen Chen
Marketing
Monsenso
+45 30 25 15 26
marketing@monsenso.com

DBT smartphone app implemented by private clinic in Denmark

DBT smartphone app implemented by private clinic in Denmark

Jul 17, 2017

DBT smartphone app by Monsenso will be implemented by the end of August

Copenhagen, Denmark – 18 July 2017 Monsenso, a Danish developer in mobile health solutions for mental health, has announced that Datlinien, a private clinic in Denmark, will soon implement the Monsenso mHealth solution with an added Dialectical Behavioural Therapy (DBT) module.
DBT is an evidence-based treatment that is commonly used to treat Borderline Personality Disorder.

Online-based DBT solutions have been found to make treatment easier to manage for clinicians, by storing information in an easily accessible place through cloud technology.

A new DBT module was recently added to the Monsenso mHealth solution as part of the mDiary Study, a research project done in collaboration with several Danish partners. The Monsenso mHealth solution, which consists of a smartphone app for individuals and a web portal for clinicians, provides a reliable, efficient, and clinically-validated smartphone based approach to DBT.

Some of the key factors of DBT include skills training and self-monitoring, which have been administered traditionally through paper-based self-assessments, workbooks and diaries. The Monsenso DBT smartphone app helps optimise and organise this process, by putting self-assessments, self-monitoring, skills training, emotion rating, and synchronized clinician feedback into one convenient location – your smartphone.

Datlinien offers mental health services, with a special focus on DBT, to public and private institutions, and they provide DBT treatment for both group and individual therapy.

Thomas Lethenborg, CEO at Monsenso, said “This new DBT module was developed as part of the mDiary Study to complement the treatment of individuals undergoing DBT treatment. It was designed to modernise the traditionally used paper-based assessments and skills training, and to make it more intuitive.”

Dr. Shahram Elahi Panah, General Manager of Datlinien, said “By adopting this new technology, we want to raise the bar on the mental health services offered by private clinics in Denmark. The Monsenso DBT smartphone app makes data collection and skills training more fun and interactive, which is great for the patients because it increases compliance and engagement. On the other hand, it is also great for us, the clinicians, because we can visualise all the patient data more easily.”

Click on the link to read the press release in Danish.

For additional information contact:

Helen Chen
Marketing
Monsenso
+45 30 25 15 26
chen@monsenso.com

The IMPACHS project funded by Eurostars is ready to start

The IMPACHS project funded by Eurostars is ready to start

Jun 28, 2017

Copenhagen, Denmark – 28 June 2017.  The IMPACHS project funded by Eureka/Eurostars and the Innovation Fund in Demark, has the aim to design, develop and provide clinical evidence for the use of smartphone-based intervention technology for outpatients diagnosed with schizophrenia, to improve the availability and cost-effectiveness of mental healthcare.

The project, with a duration of 24 months (June 2017 – June 2019) and a total budget of 1.2 million Euros, brings together leading European research/academic institutions and SMEs.

The IMPACHS project (IMProving Availability and Cost-effectiveness of mental Healthcare for Schizophrenia through mHealth), is done in collaboration between Monsenso, the Psychiatric Research Unit from Region Zealand, time4you, and the University of Hamburg.

Cognitive Behavioural Therapy (CBT) is one of the most effective psychological approaches for psychotic symptom reduction, but only 10% of patients receive it due to growing shortage of professionals [1]. Mobile-based CBT interventions (mCBT), as an adjunct to traditional care, provide a unique opportunity to deliver continuous, cost-effective, accessible, non-stigmatizing and timely support to these patients[2], promoting the detection of alarming symptoms and reducing the duration of relapses, observed in 80% of patients[3].

The IMPACHS project aims to develop mobile- and context-aware CBT content, deployed through the time4you IBT® SERVER (eLearning) platform integrated into the Monsenso Clinic mHealth solution for mental illnesses that is HIPAA compliant and has a class 1 CE mark.

The staff at the University of Hamburg have extensive knowledge on using CBT for individuals with schizophrenia and has published several research papers in medical journals related to schizophrenia.  The project will leverage their substantial experience in clinical research within schizophrenia to develop the assessments and interventions planned.

The Psychiatric Research Unit of the Zealand Region of Denmark will begin the trial using an improved version of the Monsenso Clinic that offers psycho-education through the integrated IBT e-learning platform that delivers continuous, cost-effective, and timely support to individuals with schizophrenia, complementing their therapy.

Personalised triggers, defined jointly by individuals and therapists based on a person’s behaviours, can be used to detect symptom aggravation in real-time. Mobile CBT can help lower the severity of a person’s symptoms if the content is personalised and disorder-specific.

The objective of the clinical trial is to determine the feasibility of context-aware CBT and psycho-educative content in the users’ recovery process.

With regards to the clinical trial, Thomas Lethenborg, CEO at Monsenso, commented, “Mobile-based CBT and psychoeducation is a cost-efficient solution to complement a person’s treatment. In some cases, it might be the only type of therapy that some people might be able to access, depending on the waiting list for the mental health services, and their financial or geographical situation. This type of solution may be the best way to reach more people at a lower cost.”

Dr. Hartwig Holzapfel, Director of Professional Services, said “IMPACHS opens new ways for outpatient psychotherapy and patient education. With new individualized solutions that include learning analytics and adaptive learning, patients are empowered and gain faster access and better education. Mobile Health solutions are an economical and cost-efficient way of treatment and form an important building block of modern healthcare. Within the IMPACHS-project, time4you is responsible for the technical solution based on the IBT SERVER-software, system integration, and supports partners in developing content with methodical, didactical, medical and technical expertise.”

Click on the links to read the press release in Danish

[1] Bucci et al (2015) Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. Trials 16:404

[2] Alvarez-Jimenez et al (2014) Online, social media and mobile technologies for psychosis treatment: A systematic review on novel user-led interventions. Schizophrenia Research 156 (2014) 96–106

[3] NICE Guidelines. Psychosis and schizophrenia in adults: treatment and management, [CG178]. London: Excellence NIfHaC; 2014.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 30 25 15 26
highland@monsenso.com

Axel Wolpert
Senior Consultant
time4you
+49 172 208 43 58
wolpert@time4you.de

Monsenso is a finalist for “Best eHealth solutions in Europe”

Monsenso is a finalist for “Best eHealth solutions in Europe”

Apr 20, 2017

Copenhagen, Denmark 21 April 2017 — Monsenso is a finalist for Best eHealth solutions in Europe. The Danish technology company developing mHealth solutions for mental health, was shortlisted for the Champions category. Of the 15 companies who applied in the same category, five of them were shortlisted to win the sought-after prize, which is organised by TICBioMed, with the objective to provide support for SMEs’ business success, offering a path to increase visibility and marketing opportunities to attract customers, partners and external capital.

Thomas Lethenborg, CEO at Monsenso, said, “This nomination for Best eHealth solutions in Europe is an extension of Monsenso’s growing success, driven by our commitment to establish Monsenso as an innovation leader in mHealth solutions for mental health.”

“Our efforts are underpinned by an excellent and dedicated team. The eHealth Competition is a coveted award among eHealth SMEs in Europe. The award recognises the innovation, social, demographic and economic impact of healthcare solutions, and we would like to congratulate all the finalists for their remarkable achievements,” added Mr. Lethenborg.

The finalists for the Competition of Best eHealth solutions in Europe will present their solution to the judging panel and over 700 delegates and speakers at Health 2.0, which showcases the latest innovations in healthcare, and is taking place from 3-5 May in Barcelona, Spain. The winner will be announced during the opening ceremony in Barcelona.

The Monsenso mHealth solution has been technically and clinically validated in clinical evaluation studies and randomised controlled trials (RCTs) and has a class 1 medical device CE Mark. Monsenso also holds an ISO 13485 certification, and is expected to obtain the ISO 27001 certification and become HIPAA compliant before the end of the year.

To read this press release in Danish click here.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com

Monsenso partners with Gen Re to bring mHealth solution to insurance

Monsenso partners with Gen Re to bring mHealth solution to insurance

Apr 18, 2017

Copenhagen, Denmark – 19 April 2017. Monsenso, a Copenhagen-based technology company developing mHealth solutions for mental health, today announced a partnership with Gen Re, one of the world’s leading reinsurance companies. The objective of the partnership is to help insurance companies take advantage of Monsenso’s mHealth solution, which can assist in the prevention, early intervention and treatment of mental illness.

The Monsenso mHealth solution provides practical care to people with behavioural disorders, and has the potential to improve the prevention and management of disability claims.

Patient surveys reveal that mHealth technology increases an individual’s desire to play a more active role in their treatment. With the Monsenso mHealth solution, individuals can self-monitor their lifestyle and their symptoms, helping them recover faster from mental illness.

Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. With $14 billion in capital and approx. $6 billion in premiums, it is one of the leading reinsurers in the world with a global network of offices in key reinsurance markets.

Gen Re and Monsenso will work together to help insurance companies offer an enhanced service to their customers, and reduce costs in the process. By offering the solution, insurers can actively help their customers return to work more quickly, and avoid becoming ill again

Thomas Lethenborg, CEO at Monsenso, said, “The objective of this partnership is to promote the use of mHealth technology among insurance companies.  With this technology, their customers can get better faster by receiving better mental health care, while reducing costs at the same time.”

“Monsenso is looking to build sustainable, long-term partnerships, with the ultimate goal of delivering better care, to more people, at a lower cost,” added Mr. Lethenborg.

With a desire to bring the best innovative new technology solutions to their clients, Gen Re bring their extensive insurance industry knowledge to the partnership.

Jules Constantinou, Regional Manager, Gen Re Life/Health UK & Ireland, said, “ It is important that the life insurance industry embrace new technologies and new processes in order to remain relevant in the lives of customers going forward. Clinical medicine is also evolving and we are very pleased to announce this partnership with Monsenso, which should improve outcomes for insurance claimants who are battling mental illness”.

“We anticipate working closely with Monsenso to find solutions for Gen Re’s insurance clients and their customers worldwide” added Mr. Constantinou.

With its origins at the IT University of Copenhagen, the Monsenso mHealth solution for mental illnesses holds a CE Mark. It is currently being used in a clinical capacity in the UK, Denmark, Norway, Sweden, Germany and Australia to support the treatment of a wide range of mental and behavioural disorders.

 

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com

Ross Campbell
Chief Underwriter
Life/Health Research & Development
Gen Re, UK
+ 44 (0)207 426 1803
ross_campbell@genre.com

About Gen Re
Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. We work closely with our clients to understand their strategic and operational goals, offering a wide range of products, tools and resources that aim to promote our clients’ ongoing growth and success. As a direct reinsurer, we are in the risk assumption business, just like our clients. Our shared perspective helps us understand and evaluate even the toughest risks – and propose the right solutions. Gen Re is a member of the Berkshire Hathaway family of companies, and has earned superior financial strength ratings from each of the major rating agencies.  To learn more visit:  www.genre.com

Using the Monsenso digital self-monitoring tool for borderline treatment

Using the Monsenso digital self-monitoring tool for borderline treatment

Apr 10, 2017

The Monsenso digital self-monitoring tool was tested in a pilot study by individuals with Borderline Personality Disorder in a Public-Private Innovation Partnership between The Zealand Healthcare Region and Monsenso.

The Zealand Healthcare Region, which provides medical services to more than 820,000 citizens, was looking for a smartphone-based application to replace the existing paper-based self-assessments and clinical questionnaires. The application was used in a pilot study to support the treatment of 30 patients with Borderline Personality Disorder receiving Dialectical Behavioural Therapy (DBT) and it ran from January 2016 to January 2017.

 Objectives

The main goals of the pilot study were to identify and track the triggers and early warning signs of individuals with BPD using the digital self-monitoring tool, and to evaluate the project from a Mini Medical Technology Assessment (MTV) perspective, in relation to performance, future impact on patient outcomes and financial implications.

Challenges

  • To provide patients and healthcare providers with an effective digital self-monitoring tool that is able to identify and track triggers and early warning signs
  • To optimise the treatment of BPD and to reinforce the recovery process by improving patients’ access to information about their illness
  • To configure, further develop, and install the Monsenso digital self-monitoring tool so that it can be tested in day-to-day operations in the psychiatry unit in Region Zealand

The Monsenso digital self-monitoring tool

The Monsenso mHealth solution is configured to meet the needs and track the symptoms of patients with borderline. It is based on a double-loop treatment model that connects patients and healthcare providers. The Monsenso digital self-monitoring tool gives patients the opportunity to enter and visualise self-reported data and early warning signs. At the same time, the system provides healthcare providers with access to prognosis, statistics, pattern analysis, risk, and tracking of early warning signs. The solution consists of a smartphone application for patients, and a web portal for healthcare providers. The web portal allows care providers to access all the data collected by the patients’ smartphones, and facilitates data analysis. Each clinic has access to an overview of the patients for whom they are responsible. This allows healthcare providers to monitor patients closely in order to quickly identify when the patients’ conditions are changing and document the process patients go through during their treatment.

Results

Since the 30 patients rapidly embraced the app, when the pilot was completed, they had no wish to return to the paper-based self-assessments. Therefore,  The Zealand Healthcare Region chose to extend the agreement with Monsenso for an additional year, even though the project had not been fully evaluated.

The final evaluation, which will be conducted by the Psychiatric Unit of Research of Region Zealand in Slagelse and the Consolidated Unit of Production, Research and Innovation is set to be concluded in early 2017.

The final evaluation includes a round of interviews with patients and staff, who have been testing the Monsenso solution.

Click here to watch a video displaying patient testimonials.

Click on the links below to learn more about Monsenso’s usage in the treatment of Borderline Personality Disorder: